ASC4FIRST Asciminib
ASC4FIRST: Phase III Trial of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor as First-line Therapy for Chronic Myeloid Leukemia in Chronic Phase

Released: December 11, 2024

Expiration: December 10, 2025

Activity

Progress
1
Course Completed